BMO Capital Maintains Outperform on BioNTech, Lowers Price Target to $123
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Etzer Darout maintains an Outperform rating on BioNTech (NASDAQ:BNTX) but lowers the price target from $127 to $123.

March 21, 2024 | 5:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BMO Capital maintains an Outperform rating on BioNTech but lowers the price target from $127 to $123.
While the reduction in the price target from $127 to $123 by BMO Capital might suggest a slight adjustment in valuation expectations, the maintenance of an Outperform rating indicates a continued positive outlook on BioNTech's performance. This mixed signal could lead to a neutral short-term impact on the stock, as investors weigh the lowered price target against the analyst's overall positive stance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100